Payment overview · 2025
General Payments
$15.23
1 reported records · 1 companies
Healthcare provider profile · identity verified
Larry S Mikul, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JEMISON, AL · NPI 1356454102
Verified facts
What the public records show
CMS Open Payments records show Larry S Mikul, M.D. received $15.23 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.23 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $15.23 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 533 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 481 | 161 |
| Gabapentin | Gabapentin | 426 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 129 |
| Alprazolam | Alprazolam | 320 | 55 |
| Omeprazole | Omeprazole | 293 | 83 |
| Meloxicam | Meloxicam | 277 | 92 |
| Atenolol | Atenolol | 261 | 72 |
| Losartan Potassium | Losartan Potassium | 260 | 87 |
| Metformin Hcl | Metformin Hcl | 244 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 56 |
| Methylprednisolone | Methylprednisolone | 221 | 163 |
| Lisinopril | Lisinopril | 217 | 73 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 212 | 67 |
| Azithromycin | Azithromycin | 196 | 151 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 64 |
| Ozempic | Semaglutide | 187 | 32 |
| Trazodone Hcl | Trazodone Hcl | 187 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 162 | 41 |
| Tramadol Hcl | Tramadol Hcl | 160 | 40 |
| Furosemide | Furosemide | 151 | 54 |
| Glipizide | Glipizide | 144 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 51 |
| Methocarbamol | Methocarbamol | 134 | 47 |
| Clonazepam | Clonazepam | 131 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 39 |
| Simvastatin | Simvastatin | 117 | 35 |
| Prednisone | Prednisone | 114 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 28 |
| Sertraline Hcl | Sertraline Hcl | 111 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 26 |
| Montelukast Sodium | Montelukast Sodium | 108 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 44 |
| Amoxicillin | Amoxicillin | 105 | 88 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 39 |
| Lorazepam | Lorazepam | 103 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 34 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 99 | 35 |
| Famotidine | Famotidine | 98 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 35 |
| Carvedilol | Carvedilol | 96 | 32 |
| Meclizine Hcl | Meclizine Hcl | 93 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 92 | 18 |
| Potassium Chloride | Potassium Chloride | 92 | 41 |
| Azelastine Hcl | Azelastine Hcl | 86 | 55 |
| Eliquis | Apixaban | 85 | 25 |
| Colestipol Hcl | Colestipol Hcl | 81 | 27 |
| Jardiance | Empagliflozin | 81 | 27 |
| Pregabalin | Pregabalin | 81 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 26 |
| Metformin Hcl Er | Metformin Hcl | 77 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 46 |
| Allopurinol | Allopurinol | 70 | 23 |
| Mirtazapine | Mirtazapine | 69 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 11 |
| Buspirone Hcl | Buspirone Hcl | 61 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 40 |
| Januvia | Sitagliptin Phosphate | 57 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 16 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 54 | 19 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 41 |
| Baclofen | Baclofen | 51 | 12 |
| Colchicine | Colchicine | 49 | 24 |
| Celecoxib | Celecoxib | 48 | 12 |
| Finasteride | Finasteride | 48 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 34 |
| Bupropion Xl | Bupropion Hcl | 44 | 13 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 15 |
| Levofloxacin | Levofloxacin | 43 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 15 |
| Sucralfate | Sucralfate | 42 | 16 |
| Spironolactone | Spironolactone | 39 | 11 |
| Cephalexin | Cephalexin | 37 | 28 |
| Fluconazole | Fluconazole | 37 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 15 |
| Nystatin | Nystatin | 37 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 13 |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 16 |
| Estradiol | Estradiol | 32 | 11 |
| Ezetimibe | Ezetimibe | 32 | 12 |
| Glimepiride | Glimepiride | 32 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Mupirocin | Mupirocin | 29 | 24 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 27 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | 11 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | 12 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Cymbalta | Duloxetine Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Proair Respiclick | Albuterol Sulfate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15.23 · 1 records | ABBVIE INC. | VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error